Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 450-460

  Bijman, Marcel N A ^a   Van Berkel, Maria P A ^a   Kok, Mirjam ^a   Janmaat, Maarten L ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cetuximab; Docetaxel; Human epidermal growth factor family; Ovarian cancer; Pertuzumab; Trastuzumab

Indexed keywords

CASPASE 3; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; TRASTUZUMAB;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TAXOIDS;

EID: 67249098554     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832afc24     Document Type: Article

References (46)

1. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006; 17(Suppl5):v181-v187. (Pubitemid 43994856)
2. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96:1682-1691. (Pubitemid 39585637)
3. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 2004; 58:932-940. (Pubitemid 38221153)
4. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785:232-265.
5. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12:5268-5272. (Pubitemid 44497237)
6. Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002; 85:305-310. (Pubitemid 34522990)
7. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broët P, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2004; 91:470-475. (Pubitemid 39093565)
8. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004; 92:160-166. (Pubitemid 38147385)
9. Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14:1086-1096. (Pubitemid 39603351)
10. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005; 11:8637-8643. (Pubitemid 43005911)
11. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006; 19:607-610.
12. Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, et al. Prognostic impact of Ki67, p53, human epithelial growth factor receptor 2, topoisomerase IIα, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated cells in the bone marrow. Int J Gynecol Cancer 2007; 17:1047-1055. (Pubitemid 47414831)
13. Vermeij J, Teugels E, Bourgain C, Ziangming J, In't Veld P, Ghislain V, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008; 8:3.
14. Hellström I, Goodman G, Pullman J, Yang Y, Hellström KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001; 61:2420-2423. (Pubitemid 32685817)
15. Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006; 32:180-190.
16. Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17:798-807. (Pubitemid 47063320)
17. Tuefferd M, Couturier J, Penault-Llorca F, Vicent-Salomon A, Broët P, Guatalla JP, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. Plos One 2007; 2:e1138. (Pubitemid 351597374)
18. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Sem Oncol 2006; 33:369-385. (Pubitemid 44142736)
19. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. New Engl J Med 2007; 357:39-51. (Pubitemid 47026733)
20. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-328. (Pubitemid 38482068)
21. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24:4324-4332. (Pubitemid 46630791)
22. Attard G, Kitzen J, Blagden SP, Fong PC, Prank LC, Zhi J, et al. A phase Ib study of pertuzumb, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007; 97:1338-1343. (Pubitemid 350114792)
23. Blagden SP, Kaye SB. Docetaxel in the management of ovarian cancer. Exp Rev Anticancer Ther 2005; 5:203-214. (Pubitemid 40553087)
24. Vassey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008; 98:1774-1780. (Pubitemid 351748839)
25. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45:3668-3676. (Pubitemid 15226443)
26. Kolfschoten GM, Hulscher TM, Duyndam MCA, Pinedo HM, Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 2002; 63:733-743. (Pubitemid 34457705)
27. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002; 62:5703-5710. (Pubitemid 35204725)
28. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004; 64:2601-2609. (Pubitemid 38523918)
29. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9:2316-2326. (Pubitemid 36687658)
30. Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol 1994; 32:9-15.
31. Bruno R, Hille D, Riva A, Vivier N, Bokkel Huinink WW, Van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187-196. (Pubitemid 28041598)
32. Baselga J, Carbonell X, Castañeda-Soto N-J, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23:2162-2171. (Pubitemid 46218708)
33. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006; 12:6517-6522. (Pubitemid 44799726)
34. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006; 23:1275-1284. (Pubitemid 43946149)
35. Steffensen KD, Waldstrøm M, Olsen DA, Corydon T, Lorentzen KA, Knudsen HJ, et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res 2008; 14:3278-3282.
36. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-3237. (Pubitemid 47325606)
37. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68:1953-1961.
38. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003; 63:196-206. (Pubitemid 36070440)
39. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 2003; 21:283-290.
40. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006; 24:4317-4323.
41. Gilmour LM, Macleod KG, McCaig A, Sewell JM, Gullick WJ, Smyth JF, et al. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin Cancer Res 2002; 8:3933-3942.
42. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68:5878-5887.
43. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007; 97:494-501.
44. Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005; 11:5300-5309.
45. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445:437-441.
46. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLos One 2008; 3:e2881.